The fibrinolytic enzyme system is designed to release the protease plasmin from its inactive precursor plasminogen and to localise its action to the site of its physiological substrate fibrin. The basic components of the system are, therefore, plasminogen and plasmin; agents, collectively termed plasminogen activators, which convert plasminogen to plasmin; and inhibitors of activators or plasmin which ensure that proteolysis of other susceptible proteins does not take place. This review considers the structure and properties of plasminogen and plasmin and the processes involved in the activation of plasminogen, and outlines their relationship to recent concepts of thrombolysis.
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Plasminogen SYNTHESIS AND METABOLISM
The plasma concentration of plasminogen is around 200 /Lg/ml.1 2 Its half-life in healthy men is between 1-75 and2-65 days.2Arapid rateof synthesis is inferred from the restoration of normal plasma concentrations within [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] 28 In the absence of specific inhibitors a second bond is cleaved, Arg68-Met or Lys77-Lys. It is now accepted that these cleavages in the NH2-terminal part of the molecule are due to plasmin rather than to activator.8 While splitting of the Arg56l-Val bond in glu-plasminogen alone provides a plasmin molecule with protease activity the activation rate of lys-plasminogen, formed by the cleavage of the plasmin-sensitive bonds in the NH2-terminal part of the molecule, is many times faster. 29 Probably the increased rate of activation of lys-plasminogen is determined by the conformation change which follows the release of peptide material (preactivation peptide) from the NH2-terminus, a conformational change which is also induced by the addition of omega amino-acids. The conformational change resulting from removal of the preactivation peptide may, by uncovering fibrin-binding sites, be responsible also for the more efficient adsorption of lys-plasminogen to fibrin.
The precise pathway for the activation of plasminogen is not finally established. One possibility which takes account of much of the experimental findings is represented diagrammatically in Fig. 2 . The initial event in this scheme is the formation of catalytic quantities of glu-plasmin from glu-plasminogen by the action of activator on the Arg56l-Val bond. The plasmin formed cleaves the preactivation peptide from the NH2-terminal portion of the molecule to form lys-plasminogen, and the accompanying conformational change facilitates its further cleavage by activator and the formation of the two-chain lys-plasmin molecule. This is essentially Glu -plasminogen -.
Lys 
Mechanism of thrombolysis
The recent accumulation of knowledge on the biochemistry of plasminogen and its activation together with the concurrent discovery of the fastacting a2-antiplasmin has led to new concepts of the mechanism of thrombolysis.42
The principal physiological activator is probably that derived from the vascular wall. This activator is identical or closely similar to tissue activator,43 which has been shown to be strongly adsorbed to fibrin.22 Through its lysine-binding sites plasminogen is adsorbed to specific sites on fibrinogen and is therefore present on the fibrin formed from it. In addition, plasminogen may have a somewhat higher affinity for fibrin than for fibrinogen. In the presence of fibrin and its associated plasminogen the activating properties of tissue activator are much enhanced,44 leading to the rapid localised formation of plasmin 7 at sites appropriate for the cleavage of fibrin. In-vitro studies have shown that the formation of lys-plasminogen with its associated conformational change increases its affinity for fibrin and makes it more readily activated. There is, however, no available evidence for the formation of the lys-form of plasminogen in the circulation. The physiological significance of this form of plasminogen is therefore uncertain.
When associated with fibrin the lysine-binding sites of plasmin are occupied and, as a result, its inactivation by a2-antiplasmin is very slow. In contrast, any free plasmin released into the plasma will be rapidly neutralised and the circulating fibrinogen and other susceptible proteins protected from proteolysis.
